MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines

被引:66
|
作者
Hummel, Richard [1 ,2 ]
Sie, Corina [1 ]
Watson, David I. [1 ]
Wang, Tingting [1 ]
Ansar, Alfiya [1 ]
Michael, Michael Z. [3 ]
Van der Hoek, Mark [4 ]
Haier, Joerg [5 ]
Hussey, Damian J. [1 ]
机构
[1] Flinders Univ S Australia, Med Ctr, Dept Surg, Bedford Pk, SA 5042, Australia
[2] Univ Munster, Dept Gen & Visceral Surg, D-48149 Munster, Germany
[3] Flinders Univ S Australia, Dept Gastroenterol & Hepatol, Bedford Pk, SA 5042, Australia
[4] Adelaide Microarray Ctr, SA Pathol, Adelaide, SA 5000, Australia
[5] Univ Munster, Ctr Comprehens Canc, D-48149 Munster, Germany
基金
英国医学研究理事会;
关键词
Esophageal cancer; MicroRNA; Chemotherapy; Resistance; Target; MULTIDRUG-RESISTANCE; CONFERS RESISTANCE; CARCINOMA; CHEMORADIOTHERAPY; METAANALYSIS; SURVIVAL; RECEPTOR;
D O I
10.3748/wjg.v20.i40.14904
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate expression of microRNA (miRNA) and potential targets in chemotherapy resistant esophageal cancer cell lines. METHODS: An in-vitro model of acquired chemotherapy resistance in esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) cells was used, and microRNA expression profiles for cisplatin or 5-fluorouracil (5-FU) resistant variants vs chemotherapy sensitive controls were compared using microarray and quantitative real-time polymerase chain reaction (PCR). The expression of chemotherapy-relevant genes potentially targeted by the dysregulated microRNAs in the chemotherapy resistant variants was also evaluated. RESULTS: Chemotherapy resistant sublines were found to have specific miRNA signatures, and these miRNA signatures were different for the cisplatin vs 5-FU resistant cells from the same tumor cell line, and also for EAC vs ESCC cells with resistance to the same specific chemotherapy agent. Amongst others, miR-27b-3p, miR-193b-3p, miR-192-5p, miR-378 a-3p, miR-125a-5p and miR-18a-3p were dysregulated, consistent with negative posttranscriptional control of KRAS, TYMS, ABCC3, CBL-B and ERBB2 expression via these miRNAs. CONCLUSION: The current study supports the hypothesis that microRNA expression has an impact on chemotherapy resistance in esophageal cancer. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:14904 / 14912
页数:9
相关论文
共 50 条
  • [41] The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines
    Kazmierczak, Dominika
    Jopek, Karol
    Sterzynska, Karolina
    Ginter-Matuszewska, Barbara
    Nowicki, Michal
    Rucinski, Marcin
    Januchowski, Radoslaw
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (07)
  • [42] Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer
    Xiangyang Zhang
    Min Wang
    Junyi Feng
    Bin Qin
    Chenglin Zhang
    Chengshen Zhu
    Wentao Liu
    Yaohe Wang
    Wei Liu
    Lei Huang
    Shuangshuang Lu
    Zhimin Wang
    Journal of Nanobiotechnology, 20
  • [43] MicroRNA as a New Factor in Lung and Esophageal Cancer
    Billeter, Adrian T.
    Barnett, Rebecca E.
    Druen, Devin
    Polk, Hiram C., Jr.
    van Berkel, Victor H.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2012, 24 (03) : 155 - 165
  • [44] MicroRNA provides insight into understanding esophageal cancer
    Li, Xiaobo
    Wainscott, Caitlin
    Xi, Yaguang
    THORACIC CANCER, 2011, 2 (04) : 134 - 142
  • [45] The Role of microRNA-221 and microRNA-222 in Androgen-Independent Prostate Cancer Cell Lines
    Sun, Tong
    Wang, Qianben
    Balk, Steven
    Brown, Myles
    Lee, Gwo-Shu Mary
    Kantoff, Philip
    CANCER RESEARCH, 2009, 69 (08) : 3356 - 3363
  • [46] The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines
    Stasiak, Piotr
    Kazmierczak, Dominika
    Jopek, Karol
    Nowicki, Michal
    Rucinski, Marcin
    Januchowski, Radoslaw
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (10)
  • [47] Managing Squamous Cell Esophageal Cancer
    Batra, Rishi
    Malhotra, Gautam K.
    Singh, Shailender
    Are, Chandrakanth
    SURGICAL CLINICS OF NORTH AMERICA, 2019, 99 (03) : 529 - +
  • [48] Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer
    Osumi, Hiroki
    Yoshio, Toshiyuki
    Chin, Keisho
    Ogura, Mariko
    Kumekawa, Yosuke
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Miyamoto, Yuji
    Morishige, Kenjiro
    Ishiyama, Akiyoshi
    Hirasawa, Toshiaki
    Tsuchida, Tomohiro
    Yamamoto, Yorimasa
    Fujisaki, Junko
    Igarashi, Masahiro
    Mizunuma, Nobuyuki
    GASTRIC CANCER, 2016, 19 (02) : 625 - 630
  • [49] ASSESSMENT OF THE RESPONSE TO CHEMOTHERAPY IN ESOPHAGEAL CANCER
    WALKER, SJ
    ALLEN, SM
    STEEL, A
    CULLEN, MH
    MATTHEWS, HR
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1991, 5 (10) : 519 - 522
  • [50] Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN
    Jin, Ying-ying
    Chen, Qing-juan
    Xu, Kun
    Ren, Hong-tao
    Bao, Xing
    Ma, Yi-nan
    Wei, Yang
    Ma, Hong Bing
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2016, 422 (1-2) : 161 - 170